Holen Sie sich die Stockscreener-App
3.0435
1.44%
0.0335
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Globe and Mail
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Motley Fool
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory? - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects - Yahoo Finance
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Morgan Stanley Raises its Price Target on Recursion (RXRX) - Insider Monkey
8 Most Oversold AI Stocks to Buy According to Analysts - Insider Monkey
RXRX (NASDAQ) Form 144: 40,000 Class A shares proposed sale via Fidelity - Stock Titan
Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet? - Sahm
Recursion Pharmaceuticals (RXRX) price target decreased by 10.64% to 6.12 - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Initiatives - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CSO RSU tax withholding on 26,657 shares - Stock Titan
Recursion (NASDAQ: RXRX) CEO has 62,701 shares withheld for RSU taxes - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO reports tax-related share withholding - Stock Titan
22,821 RXRX shares withheld for taxes as Recursion director reports RSU event - Stock Titan
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - The Chronicle-Journal
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News - TechStock²
Recursion Pharmaceuticals stock hits 52-week low at $2.79 - Investing.com India
Recursion Pharmaceuticals stock hits 52-week low at $2.79 By Investing.com - Investing.com Canada
RXRX Stock Price and Chart — NASDAQ:RXRX - TradingView
Q4 Earnings Estimate for RXRX Issued By KeyCorp - MarketBeat
Nvidia’s expanding role in AI-driven drug discovery, clinical research could fuel growth, says Goldman Sachs - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 - Moomoo
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating - marketscreener.com
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities - The Globe and Mail
Recursion Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.64, Implies 118% Upside - TradingView
Recursion Pharmaceuticals (RXRX) stock dips while market gains: Key facts - MSN
Recursion Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-05-13 - Seeking Alpha
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Recursion Q1 2026 slides: AI pipeline advances amid revenue challenges - Investing.com
State Street (RXRX) discloses 28.49M-share, 5.5% stake in Recursion - Stock Titan
4 top AI stocks to hold for a decade | 2026-05-12 | Investing News - Stockhouse
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks - simplywall.st
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates - Sahm
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M - MSN
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 - Investing.com
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):